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This paper is focused in some aspects of maternal exposure to misoprostol during perinatal period, and 
the abortive and teratogenesis effects on the fetus. The causes of malformations were revised, taking into 
account chemical, physical and environmental factors as well as the interaction between them. There 
are evidences that the practice of abortion tripled in Southern and Northeastern Brazil in 15 years, and 
one of the most frequent forms of abortion is through the use of misoprostol. In Brazil, 1991, 288,700 
women were hospitalized as a consequence of complications induced by abortion attempt with this 
medicine. This fact resulted in the ban of misoprostol across our country, by Decree 344/98 determined 
by the Health Ministry. The use of misoprostol requires special control and it is allowed only in hospitals, 
with supervision of the municipal health surveillance. Among the more severe problems affecting the 
non-aborted child is the injury on the central nervous system, which frequently results in the Moebius 
syndrome. This is a congenital and non-progressive paralysis of the VI and VII cranial nerves, frequently 
bilateral, which produces a unexpressive facial appearance and convergent Strabismus. Even banned 
in our country, abortion is illegally practiced, being deprived of proper knowledge about misoprostol 
teratogenic effects on the fetus as well as the risks involving mothers. 
Uniterms: Perinatal toxicology. Misoprostol. Malformations. Moebius syndrome. Abortion. Cytotec®. 
Este trabalho enfoca aspectos relativos à exposição ao misoprostol no período perinatal como abortificante 
e agente teratogênico, assim como as causas das malformações, considerando-se fatores químicos, físicos 
e ambientais. A prática do aborto triplicou nas regiões Sul e Nordeste em 15 anos, sendo que entre os 
métodos mais freqüentes está o uso do medicamento com o princípio ativo do misoprostol. Em 1991 no 
Brasil, 288.700 mulheres foram socorridas em hospitais devido a complicações por indução de aborto 
com este medicamento. Isso resultou na proibição do misoprostol em todo país por determinação da 
portaria 344/98 do Ministério da Saúde, que exige um controle especial, onde sua utilização é permitida 
apenas em hospitais e com supervisão da vigilância sanitária municipal. Um dos problemas mais graves 
que a criança não abortada apresenta é uma injúria em seu sistema nervoso central desenvolvendo a 
Síndrome de Moebius. Esta é uma paralisia congênita e não progressiva do VI e do VII nervos cranianos, 
freqüentemente bilateral, que produz uma aparência facial pouco expressiva e estrabismo divergente. 
Neste sentido, mesmo sendo proibido em nosso país, o aborto induzido por misoprostol é praticado 
ilegalmente e sem uma verdadeira instrução da paciente sobre os efeitos teratogênicos do mesmo para 
ela e para seu bebê. 
Unitermos: Toxicologia perinatal. Misoprostol. Malformações. Síndrome de Moebius. Aborto. Cytotec®.
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INTRODUCTION
Abortion and teratogenesis 
Along the history of many people, the presence of 
abnormalities in animals or children has received different 
interpretations; from the deification of individuals up to 
their complete rejection (Bernardi, Górniak, 2006). 
In 1960, when the thalidomide, a sedative hypnotic 
drug used to treat nausea and vomiting during pregnancy, 
was recognized as the cause of a tragedy(Sanseverino et al., 
2001), necessary attention was finally given to the effects of 
several environmental agents and/or exposure to chemicals 
during the perinatal period. In Germany and other countries, 
the use of thalidomide was responsible for numerous cases 
of a rare teratogenesis, the phocomelia. This teratogenesis 
is characterized by the reduction of members associated 
with other anomalies such as mental retardation, congenital 
heart disease, and renal, intestinal and ocular anomalies 
(McBride, 1991; Bernardi, Górniak, 2006). 
Until that time, the toxicity tests required for the 
release of a drug by the Regulatory agencies included 
only studies in a single generation and only one species, 
usually a rodent (rats or mice). This procedure was the 
cause of the thalidomide tragedy. In fact, although the 
perinatal toxicity tests have been performed with this drug, 
the experimental animal employed was the rat, which is 
not sensitive to thalidomide teratogenic effects, unlike the 
mice (McBride, 1991).
From these events, Regulatory Agencies responsible 
for drugs release began to require more complex perinatal 
tests performed in multigenerational studies of, at least, 
three animal species, and at least one non-rodent (Niebyl, 
1983). 
Another important fact is that for the drugs testing, 
different doses should be used, including concentrations 
of three to five times higher than the therapeutic dose, and 
not generally used in studies to measure the effectiveness, 
such as the so called ‘maximum tolerated dose’ (MTD) 
(WHO, 1981). 
The World Health Organization (WHO) adopted a 
broader definition of pharmacovigilance, and currently 
promotes a policy of rational use of drugs through various 
programs, such as the Drug Action Program on Essential 
Drugs and Vaccines (DAP). This program covers the need 
for constant evaluation of all aspects of cases involving 
drugs, the need for quality of drug therapy by health pro-
fessionals, and the patients’ and community responsibility 
in the process of pharmacovigilance (WHO, 1981).
The main objective is the establishment of policies 
and strategies for a rational use, involving the regulation 
of advertising and the development of effective systems 
of information on medicines. Still, the need to correctly 
establish the following requirements for medications use 
and dose period, ensures medications quality, safety and 
efficacy (Osorio-de-Castro et al., 2004). 
Thus, the drug, studied just before the clinical 
pharmacology and therapeutic tool, has an interest in the 
epidemiology, involving the extent of use in populations 
and the detection of risk associated with their use. These 
studies are a valuable weapon for the quality assessment 
of care provided to a community by government (Osorio-
de-Castro et al., 2004). 
In this sense, the development of animals can be 
affected by pathological, chemical and environmental 
agents. Thus, among the pathological factors, one can 
mention: 1) the heredity caused by inheritance of genes 
and chromosomal combinations that result in defects 
related to sex or not, determining a higher incidence of 
malformation in offspring, 2) maternal or fetal disease, for 
example, toxoplasmosis, hyperthermia, cytomegalovirus, 
producing teratogenesis and even fetal death. Respecting 
chemical factors, medicines, pollutants and pesticides are 
important in medicine. Moreover, environmental factors 
include the variables nutrition, physical factors and stress 
(Bernardi, Górniak, 2006).
Perinatal death
The term “perinatal death” was proposed by Peller 
in 1940 that thought must obtain statistical data of children 
born dead and those dying after the first week neonatal 
(Laurenti, Buchalla, 1985). 
To understand the causes of infant mortality, it is 
necessary first to know the causes of perinatal mortality. 
Through variables such as maternal age, smoking status, 
prenatal care, previous pregnancies, birth order and birth 
weight, the maternal factors fetal and maternal-fetal and 
environmental were evaluated (Laurenti, Buchalla, 1985). 
The passage of drugs from maternal blood to the 
embryo / fetus during pregnancy will depend mainly on 
the type of placentation, the physicochemical properties 
of the agent and promoted by biotransformation placenta 
(Bernardi, Górniak, 2006). 
Maternal disorders contribute considerably to har-
mful effects of drugs in the perinatal period. We must con-
sider that maternal body presents pharmacokinetic changes 
induced by the pregnancy and type of placenta, different 
in different species, determines the degree of exposure of 
the concept to various substances (Chagas et al., 2007). 
Therefore, to call a drug ‘teratogenic’ (from the 
Greek, Derati = monster), it should be able to increase 
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the frequency of a functional or structural abnormality 
in the offspring of certain species, when administered to 
parents before conception or to mother in a critical period 
of pregnancy (Bernardi, Górniak, 2006). 
Selection of drugs for use during pregnancy 
Under certain conditions, it is necessary the use of 
drugs to treat symptoms or intercurrent diseases or preg-
nancy of their own. A list of drugs that are affecting the 
neonatal morphology and/or brain development and some 
of the toxic signs based on their pharmacological actions. 
The drugs were classified with clinical use in the following 
categories according to risk offered in pregnancy (Briggs 
et al., 1994). 
Category A: Controlled studies in women showed no 
risk to the fetus in the first quarter of pregnancy (without 
evidence of risk in later quarters) and the possibility of fe-
tal injury seems remote. It includes few drugs as multivita-
mins or prenatal vitamins, except for mega doses of them. 
Category B: studies in animals showed no fetal risk, 
but there are no controlled studies in pregnant women, 
or had any adverse effect on animals (excluding decre-
ase in fertility) and not confirmed in controlled studies 
in pregnant humans (and there is no evidence of risk in 
subsequent quarters). Include several classes of drugs of 
common use, such as penicillins. 
Category C: Studies in animals have revealed ad-
verse effects on the fetus (teratogenic or embryogenic, 
or both) and no controlled studies in women, or they are 
not available in women and in animals. It should only be 
given if the expected benefit justifies the potential risk to 
the fetus. Examples: fluoroquinolones, fluconazole, itra-
conazole and others. 
Category D: There is evidence of risk to the human 
fetus, but the benefits of their use may justify the risk (e.g., 
if the drug is needed in situations of imminent risk of life or 
in case of serious illness, there are no more alternative me-
dicines safe and effective). Carbamazepine is an example. 
Category X: Studies in animals and humans have 
demonstrated fetal abnormalities or there is risk based 
on human experimentation, or both. The risk of use in 
pregnant women clearly outweigh any potential benefit. 
The drug is contraindicated in women who are or intend 
to become pregnant. Isotretinoin, that is indicated for 
the treatment of acne and can cause various neurological 
abnormalities, facial and cardiovascular abnormalities, is 
an example. 
The best option in the clinical use of drugs during 
pregnancy is the use of drugs with longer experience of 
use. In fact, the largest clinical experience allows a better 
assessment of safety and even to change its teratogenic 
status, justifying this conduct (Briggs et al., 1994). 
Koren et al. (1998) list choice and alternative me-
dicines for use in specific situations in pregnancy. Fortu-
nately, most products do not seem exert adverse effects 
on the fetus. 
Misoprostol 
Misoprostol is a synthetic prostaglandin E1, initially 
introduced in the market for the treatment of gastritis and 
peptic ulcer resulting from the use of non-hormonal anti-
inflammatory. Costumes marketed under the names of 
Cytotec® (Searle) and Protokos® (Hebron S/A), shown in 
the 80’s, when used during the first quarter of pregnancy 
can cause uterine contractions able to stop an early preg-
nancy (Feitosa et al., 2006). The same seems to be ine-
ffective in 50% of cases. This fact is related to the number 
of tablets used, the route of use (oral, vaginal or oral and 
vaginal together), the gestational period and individual 
susceptibility (Cavalcante et al., 2005). 
Misoprostol causes a transient drop in the circulation 
of the fetus that depends on the intensity in the vascular 
phenomenon, its time for action and the time of occurrence 
can cause most of the congenital anomalies (Moreira et 
al., 2001). 
Used for induction of labor in cases of intra-uterine 
death and the fetus alive, prolonged pregnancies, pree-
clampsia, diabetes, restrictions on fetal size, or in cases 
of cervical unfavorable situation to achieve a success of 
75% to 95 % of cases, varying according to the method of 
administration (Feitosa et al., 2006). In laboratory animals, 
produces severe abnormalities when administered on the 
third day of pregnancy, called the deployment period 
(Moraes et al., 2000). 
According to Moreira et al. (2001), estimates made 
from INAMPS (National Institute of Health Care Social 
Security) data and incomplete statistics on abortions in pri-
vate clinics in South and Northeast show that the practice 
of abortion in these regions tripled in 15 years. Moreover, 
among the used resources there are more abortive teas, 
herbal infusions, medicinal and misoprostol. The use of 
misoprostol was found in attempts to abortion generally 
used when the dosage of 4 tablets, 2 oral (sublingual) and 
2 vaginal (Moreira et al., 2001). 
In 1991 in Brazil, 288,700 women were helped in 
hospitals because of complications in abortion induction 
with misoprostol. Its use can cause severe pain, heavy 
bleeding, nausea, vomiting and diarrhea and can increase 
the complications in proportion to the period of gestation 
(Rose et al., 2006). 
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Cavalcante et al. (2005), reported in a study with 15 
mothers of children diagnosed with Moebius Syndrome, 
which 66.7% of women attempted abortion with miso-
prostol by combined (oral and vaginal), and the average 
was 4 tablets , 8 per woman. The authors also reported that 
all women in the study made the attempt in the first three 
months of pregnancy. 
Due to high occurrence of these cases, the sale of 
Cytotec® was prohibited throughout the country by de-
cree 344/98 establishing the Ministry of Health, and its 
permitted use only in hospitals (Cavalcante et al., 2005). 
The use of Cytotec® is approved in hospitals for the 
induction of labor with immature cervix and alive fetus, 
it is considered as or more efficient than the natural pros-
taglandins and more efficient than the oxytocin. Feitosa 
et al. (2006) conduced studies concerning the induction 
of labor involving 40 women at high risk in two hospital-
schools in the period July to December 2003. Resulting in 
a margin of 95% of deliveries in approximately 24 hours 
after its induction with misoprostol. The route usually 
used in these cases is sublingual what can be explained 
by the absence of first pass liver, and its almost neutral pH 
(Feitosa et al., 2006). 
The Moebius syndrome 
The Moebius syndrome is characterized by congeni-
tal and not Progressive palsy, of VI and VII pairs of cranial 
nerves, often bilateral, which produces a unexpressive 
facial appearance and divergent strabismus (Moebius, 
1988). Other cranial nerves may be present committed 
(???), unilateral or bilateral, determining ptosis, deafness, 
disturbances of sensation in the territories innervated by 
the trigeminal, dysphagia, dysphonia and atrophy of the 
tongue, which can be found in different combinations 
(Cavalcante et al., 2005) . 
Mental retardation is usual, suggesting the invol-
vement of the nervous system, skeletal malformations 
occur in many cases, particularly characterized by the 
presentation of crooked feet. Micrognathia and aplasia of 
the pectoral are also observed and in this case are called 
Polland syndrome (Marti-Herrero et al., 1998). Other 
abnormalities have been described, such as defects of the 
extremities, teeth, heart and central respiratory dysfunction 
(Carneiro, Gomes, 2005). 
The origin of the Moebius Syndrome is speculative, 
but certainly is influenced by genetic and environmental 
factors, and the fetal transient ischemia is the most ac-
cepted theory to explain the syndrome (Dotti et al., 1989, 
Volpe, 1995). Thus, any change that adversely affects the 
blood flow of the placenta to the fetus, in a time of ges-
tation, could result in aplasia or hypoplasia of the facial 
nerve nuclei of the motor and external eye in the brainstem. 
Although most cases are sporadic, some scholars 
suggest a genetic origin for the syndrome. Among them, 
Dotti et al. (1989) described evidence of dominant inhe-
ritance in two families and Ziter et al. (1977) recognized 
that the translocation between the short arm of chromo-
some 1 and the long arm of 13 were responsible for cases 
of Moebius syndrome in the same family. Environmental 
factors have been implicated in the genesis of Moebius 
Syndrome, such as hyperthermia, exposure of pregnant 
women to infection, use of misoprostol, alcohol, cocaine, 
thalidomide and the benzodiazepines, among others. 
According to Carneiro and Gomes (2005), the Mo-
ebius syndrome is a rare disease, but their frequency has 
increased in our society because of the use of misoprostol 
in pregnant women. 
Abortion is a very old method of birth control prac-
ticed by all civilizations, although it is recognized that in 
many countries it is banned in almost all Latin America, 
which does not prevent the illegal practice in Brazil (Mo-
reira et al., 2005). The factors leading to this act are usu-
ally inadequate financial condition, domestic violence, a 
project of life, unemployment, numerous offspring, among 
others (Gesteira et al., 2006). 
The abortion in Brazil is a public health problem, 
due to its high incidence. According to studies (Schuler-
Faccini et al., 2002), it is estimated that about 15% of 
recognized pregnancies end in abortion and that 3 to 5% of 
all newborns have a living congenital defect when coming 
from frustrated attempts to abortion . 
The biggest problem currently is the interrela-
tionship between the use of misoprostol as abortive that 
exposes the fetus and mother to numerous risks and se-
quelæ, one of which may be the increase in the number of 
cases of Moebius syndrome in newborns. 
As a way of preventing the marketing of the drug, 
Cytotec® was banned from the market being used only in 
hospitals (Cavalcante et al., 2005). 
CONCLUSIONS 
The abortion in Brazil is a public health problem, 
there is seen to its high incidence. One of the drugs most 
used for induction of illegal abortion is misoprostol. Be-
sides the risks of maternal bleeding, the frequent develop-
ment of teratogenesis in children exposed to misoprostol, 
in which there was no success in trying to abortion occurs. 
You need clarification of the pregnant women about the 
risk of abortion with the use of this product. It will be 
interesting to clarify all women of childbearing age about 
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the risks of abortion and of contraceptive methods to avoid 
the use of medicines to end abortion. 
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